Advertisement

ASCO GU 2024: Adjuvant Pembrolizumab for Clear Cell RCC
Posted: 02/21/2024 | By: Sarah Campen, PharmD

Results from a prespecified interim analysis of the KEYNOTE-564 trial—which investigated adjuvant pembrolizumab vs placebo following nephrectomy in patients with clear cell renal cell carcinoma—were presented at the 2024 ASCO Genitourinary Cancers Symposium (Abstract LBA359).

Question 1 of 5

KEYNOTE-564 is the first phase III study to show:

Choose 1

A
Improved survival with any neoadjuvant therapy in renal cell carcinoma
B
Improved survival with any adjuvant therapy in renal cell carcinoma
C
Improved survival in patients with low-risk renal cell carcinoma
D
Improved survival in patients with renal cell carcinoma without surgical resection

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage